In our study [42], ACt ± trastuzumab was associated with a significantly reduced risk of recurrence, including distant recurrence, in infra-centimetric node-negative HER2-positive BC and most of the benefit may have been driven by pT1b tumors. This evidence concerns the gene ERBB2 and breast cancer.